Actively Recruiting
FTT PET/CT in Pancreatic Neuroendocrine Tumors
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-02-02
12
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
Sponsors
A
Abramson Cancer Center at Penn Medicine
Lead Sponsor
U
University of Pennsylvania
Collaborating Sponsor
AI-Summary
What this Trial Is About
A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging assessment using a whole-body PET CT scanner. Dynamic images will be obtained beginning immediately prior to the administration of 10 mCi of \[18F\]FTT (±20%) for a total of 60 minutes. A static scan may subsequently be obtained up to 90 minutes post radiotracer injection, per the PI's discretion. \[18F\]FTT uptake will be measured on the PET scan and correlated with two molecular outcomes.
CONDITIONS
Official Title
FTT PET/CT in Pancreatic Neuroendocrine Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be 18 years of age or older.
- Clinical diagnosis of metastatic or unresectable grade 1, grade 2, or grade 3 pancreatic neuroendocrine tumor.
- Have at least one lesion on clinical imaging that is 1.5 cm or larger in size.
- May be currently receiving any form of treatment or not receiving treatment.
- Willing to consent to use of tumor tissue collected from previous studies or clinical procedures.
- Able to provide informed consent and participate according to institutional and federal guidelines.
You will not qualify if you...
- Patients who have received liver directed therapy that treated all of their disease and have not yet shown disease progression.
- Inability to tolerate imaging procedures as judged by an investigator or treating physician.
- Females who are pregnant or breastfeeding are not eligible; women of child-bearing potential will have a urine pregnancy test before tracer injection.
- Any current medical condition or illness that could compromise safety or successful participation as assessed by medical review or self-report.
- Individuals who cannot understand or give informed consent or who are mentally disabled.
- Children, fetuses, neonates, or prisoners are not included in the study.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Pennsylvania, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
E
Erin K Schubert, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here